Q3 2021 Demant A/S Interim Management Statement Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Julien Ouaddour - Exane BNP Paribas, Research Division - Analyst : First question on the EBIT guidance. So could you maybe rank by order of import and which division within hearing health care has driven the most of the EBIT guidance upgrade in H2. So I mean, between wholesale, retail and diagnostics. Then second question is, are you still confident and maybe you talk about it in the -- like in your presentation, but I'm still confident that the communications underlying market would grow around 12% in 2022. And this, despite, I would say, the current supply chain issue and the lack of component that we might see today in this market?

Question: Julien Ouaddour - Exane BNP Paribas, Research Division - Analyst : Just for the, I would say, EBIT margin guidance. Also maybe the question is how big, I would say, the French reform and the French market has, I would say, impacted this upgrade?

Question: Daniel Jelovcan - Mirabaud Securities Limited, Research Division - Analyst : Just one question. To the different countries, I mean, just curious, you mentioned South Korea and Turkey was strong. Was that mainly Oticon More or, I guess, it's probably more the Philips brand. And also, China, you mentioned that growth in your hearing aid was modest. But I think the market was quite strong. I'm trying to understand that because Philips is quite strong as a brand in general in China. So where is the delta here? And then Germany, I understand the high base, but are there some other elements why Germany is not so good at the moment?

Question: Daniel Jelovcan - Mirabaud Securities Limited, Research Division - Analyst : And maybe a follow-up on NHS. I mean why is it now recovering also of a sudden now?

Question: Daniel Jelovcan - Mirabaud Securities Limited, Research Division - Analyst : And that was the case since when?